



## **AIFA approves Comirnaty vaccine for ages 5 to 11**

On 1<sup>st</sup> December 2021 the AIFA Scientific-Technical Committee (CTS) approved the extension of indication of use of the Comirnaty (Pfizer) vaccine for the 5-11 years age group, with a reduced dose (one third of the authorised dosage for adults and adolescents) and with a specific formulation. The vaccination will take place in two doses three weeks apart. The CTS points out that the available data show a high level of efficacy and no safety signals have been reported to date.

To avoid any administration error, the CTS recommends that the above age group be exclusively administered the *ad hoc* pediatric formulation, suggesting vaccination courses appropriate to age, where possible.

In its opinion, the CTS notes that “although SARS-CoV-2 infection is certainly more benign in children, in some cases it can be associated with serious consequences, e.g. the risk of developing multisystem inflammatory syndrome (MIS-c), which may also require hospitalisation in intensive care unit”. Finally, the CTS highlights that “vaccination brings benefits such as the possibility of attending school and leading a social life with valuable recreational and educational elements, particularly important for mental and personality development in this age group”.